| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
41,774 | 37,046 | 25,161 | 19,696 | 0 | 0 | 0 |
General and administrative | ||||||
10,744 | 8,605 | 5,996 | 3,814 | 0 | 0 | 0 |
Total operating expenses | ||||||
52,518 | 45,651 | 31,157 | 23,510 | 0 | 0 | 0 |
Loss from operations | ||||||
-52,518 | -45,651 | -31,157 | -23,510 | 0 | 0 | 0 |
Other income (expense): | ||||||
Interest income | ||||||
0 | - | - | - | 0 | - | - |
Change in fair value of preferred stock tranche obligation | ||||||
- | - | - | - | - | 0 | - |
Change in fair value of anti-dilution right liability | ||||||
- | - | - | - | - | 0 | 0 |
Other expenses | ||||||
- | - | - | - | 0 | - | - |
Total other income, net | ||||||
2,239 | 1,896 | -8,135 | -8,901 | 0 | 0 | 0 |
Net loss | ||||||
-50,279 | -43,755 | -39,292 | -32,411 | 0 | 0 | 0 |
Net unrealizable gain on marketable securities | ||||||
0 | - | - | - | - | - | - |
Comprehensive loss | ||||||
0 | - | - | - | 0 | - | - |
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | - | - | - | 0 | 0 |
Net loss attributable to common stockholders | ||||||
- | - | 0 | 0 | - | 0 | 0 |
Net loss per common share, basic and diluted | ||||||
-0.42 | 31.77 | -0.56 | -2.21 | -31.90 | -89.66 | -94.86 |
Weighted-average number of shares used in computing net loss per common share, basic and diluted | ||||||
28,499 | 28,821 | 28,024 | 3,268 | 168 | 127 | 92 |